AR057378A1 - Formulaciones de diclofenac y metodos para usarlas - Google Patents
Formulaciones de diclofenac y metodos para usarlasInfo
- Publication number
- AR057378A1 AR057378A1 ARP060102600A ARP060102600A AR057378A1 AR 057378 A1 AR057378 A1 AR 057378A1 AR P060102600 A ARP060102600 A AR P060102600A AR P060102600 A ARP060102600 A AR P060102600A AR 057378 A1 AR057378 A1 AR 057378A1
- Authority
- AR
- Argentina
- Prior art keywords
- diclofenac
- formulations
- formulation
- phonophobia
- photophobia
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 8
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 title abstract 4
- 229960001259 diclofenac Drugs 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 abstract 6
- 208000019695 Migraine disease Diseases 0.000 abstract 4
- 206010027599 migraine Diseases 0.000 abstract 4
- 206010054956 Phonophobia Diseases 0.000 abstract 3
- 206010034960 Photophobia Diseases 0.000 abstract 3
- 208000002193 Pain Diseases 0.000 abstract 2
- 208000005298 acute pain Diseases 0.000 abstract 2
- 239000012669 liquid formulation Substances 0.000 abstract 2
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000002459 sustained effect Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Biomedical Technology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Se proporcionan métodos y formulaciones para tratar la migrana y otros episodios de dolor agudo usando diclofenac, y formulaciones de diclofenac que proporcionan el alivio rápido y sostenido del agudo. También se proporcionan métodos y formulaciones para tratar los síntomas que comunmente acompanan la migrana y el dolor agudo, tales como la fotofobia, la fonofobia, la náusea y los vomitos. Reivindicacion 1: Un método para tratar la migrana asociada con fonofobia o fotofobia en un paciente humano, caracterizado porque comprende: a) proporcionar una formulacion líquida que comprende 50 mg. de diclofenac, o una sal de éste aceptable para el uso farmacéutico, donde dicha formulacion: i) se proporciona como una formulacion en polvo y se disuelve o se suspenda en agua inmediatamente antes de la administracion, o como una formulacion líquida que se ingiere con o sin una mezcla adicional; ii) opcionalmente permite obtener una Cmax de entre aproximadamente 1.500 y aproximadamente 2.500 ng./ml.; y iii) alcanza tmax en entre aproximadamente 10 y aproximadamente 25 minutos; y b) administrar por vía oral dicha formulacion a un paciente que sufre migrana asociada con fotofobia o fonofobia.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69175705P | 2005-06-17 | 2005-06-17 | |
| US69202405P | 2005-06-17 | 2005-06-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR057378A1 true AR057378A1 (es) | 2007-11-28 |
Family
ID=37396065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060102600A AR057378A1 (es) | 2005-06-17 | 2006-06-20 | Formulaciones de diclofenac y metodos para usarlas |
Country Status (24)
| Country | Link |
|---|---|
| US (7) | US7759394B2 (es) |
| EP (4) | EP2402003B1 (es) |
| KR (1) | KR101352130B1 (es) |
| CN (3) | CN104856959A (es) |
| AR (1) | AR057378A1 (es) |
| AU (1) | AU2006257072B2 (es) |
| BR (1) | BRPI0612245A2 (es) |
| CA (2) | CA2932603C (es) |
| EC (1) | ECSP077989A (es) |
| ES (3) | ES2641889T3 (es) |
| GT (1) | GT200600261A (es) |
| HK (1) | HK1213814A1 (es) |
| JO (1) | JO3352B1 (es) |
| MX (1) | MX2007016072A (es) |
| NO (1) | NO342336B1 (es) |
| NZ (1) | NZ564002A (es) |
| PE (1) | PE20070074A1 (es) |
| PL (1) | PL1890680T3 (es) |
| PT (1) | PT1890680T (es) |
| RU (1) | RU2432160C2 (es) |
| TR (1) | TR201706038T4 (es) |
| TW (1) | TW200740470A (es) |
| WO (1) | WO2006133954A2 (es) |
| ZA (1) | ZA200710858B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6974595B1 (en) * | 1996-05-17 | 2005-12-13 | Proethic Pharmaceuticals, Inc. | Pharmaceutical compositions based on Diclofenae |
| JO3352B1 (ar) * | 2005-06-17 | 2019-03-13 | Apr Applied Pharma Res Sa | صيغ دايكلوفيناك وطرق استخدامه |
| US7700125B2 (en) * | 2006-02-07 | 2010-04-20 | Kowa Pharmaceuticals America, Inc. | Moisture resistant container systems for rapidly bioavailable dosage forms |
| US20100215736A1 (en) * | 2007-05-24 | 2010-08-26 | Novartis Ag | Oral dosage form providing fast adsorption of drug |
| MY159208A (en) | 2009-04-24 | 2016-12-30 | Iceutica Pty Ltd | A novel formulation of indomethacin |
| EP2421525B1 (en) * | 2009-04-24 | 2017-06-07 | Iceutica Pty Ltd. | Diclofenac formulation |
| US20120183611A1 (en) * | 2009-09-25 | 2012-07-19 | Norvartis Ag | Oral pharmaceutical composition comprising diclofenac |
| FR2984165B1 (fr) * | 2011-12-16 | 2014-06-27 | Pharmeuro | Traitement des crises de migraines, notamment d'algies vasculaires de la face |
| US9526734B2 (en) | 2014-06-09 | 2016-12-27 | Iceutica Pty Ltd. | Formulation of meloxicam |
| US9855234B2 (en) | 2014-07-08 | 2018-01-02 | Insys Development Company, Inc. | Diclofenac sublingual spray |
| CN106580886A (zh) * | 2016-12-05 | 2017-04-26 | 北京万全德众医药生物技术有限公司 | 一种双氯芬酸钾散剂及其制备方法 |
| WO2019030773A1 (en) * | 2017-08-10 | 2019-02-14 | Sarudbhava Formulations Private Limited | DICLOFENAC COMPOSITIONS WITH LOW DOSE |
| EP3893865A1 (en) | 2018-12-14 | 2021-10-20 | Apr Applied Pharma Research S.A. | Ready to use diclofenac stick packs |
| AU2021286957A1 (en) * | 2020-06-10 | 2023-02-09 | Apr Applied Pharma Research, S.A. | Bioavailable sugar-based diclofenac formulations |
| EP3928766A1 (en) | 2020-06-26 | 2021-12-29 | Usso Barnas | Pharmaceutical composition and use thereof |
| US20220241230A1 (en) * | 2021-02-03 | 2022-08-04 | Patrin Pharma, Inc. | Diclofenac sachet composition |
| CN115317464B (zh) * | 2022-09-01 | 2023-08-08 | 苏州弘森药业股份有限公司 | 一种双氯芬酸钾微胶囊及其制备方法 |
| GB2634218A (en) * | 2023-09-29 | 2025-04-09 | Approved Pharma Solutions Ltd | Powder for oral solution formulations |
| GB202401873D0 (en) * | 2024-02-12 | 2024-03-27 | Hawkins John | Lipophilic drug suspensions |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3558690A (en) | 1965-04-08 | 1971-01-26 | Gelgy Chemical Corp | Substituted derivatives of 2-anilinophenylacetic acids and a process of preparation |
| US4344929A (en) * | 1980-04-25 | 1982-08-17 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| JPS57191962A (en) | 1981-05-20 | 1982-11-25 | Hitachi Ltd | Fuel cell |
| IT1209667B (it) | 1985-11-12 | 1989-08-30 | Zambon Spa | Composizione effeverscente adattivita' analgesica. |
| CH673395A5 (es) * | 1987-01-30 | 1990-03-15 | Ciba Geigy Ag | |
| US5211957A (en) * | 1988-03-25 | 1993-05-18 | Ciba-Geigy Corporation | Solid rapidly disintegrating dosage form |
| IT1226549B (it) | 1988-07-12 | 1991-01-24 | Resa Farma | Composizioni farmaceutiche ad attivita' analgesica ed antiinfiammatoria per uso orale, dotate di ottima palatabilita' ed esenti da effetti irritanti sulle mucose. |
| GB8824392D0 (en) | 1988-10-18 | 1988-11-23 | Ciba Geigy Ag | Dispersible formulation |
| GB8920693D0 (en) | 1989-09-13 | 1989-10-25 | Nicholas Kiwi Pty Ltd | Non-effervescent ibuprofen compositions |
| DE59105562D1 (de) | 1990-06-28 | 1995-06-29 | Ciba Geigy Ag | Alpha-Carbonylphenylacetonitrilderivate als Stabilisatoren für organische Materialien. |
| EP0466650A2 (en) | 1990-07-11 | 1992-01-15 | Warner-Lambert Company | Improvements in non-steroidal anti-inflammatory therapy |
| MX9300110A (es) * | 1992-01-13 | 1994-07-29 | Gerhard Gergely | Preparacion farmaceutica en la forma de una tableta de efervescencia o de desintegracion o de un granulado de tipo instanteneo y procedimiento para su preparacion. |
| NZ253999A (en) * | 1992-08-05 | 1996-07-26 | Faulding F H & Co Ltd | Pelletised substained release medicament |
| IT1264696B1 (it) | 1993-07-09 | 1996-10-04 | Applied Pharma Res | Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata |
| ES2133454T3 (es) | 1993-09-07 | 1999-09-16 | Gergely Gerhard | Mezcla efervescente con sales alcalinas o lisinatos de principios activos acidos, insolubles o dificilmente solubles. |
| US5458879A (en) * | 1994-03-03 | 1995-10-17 | The Procter & Gamble Company | Oral vehicle compositions |
| BR9507768A (pt) | 1994-05-27 | 1997-09-02 | Farmarc Nederland Bv | Composição farmacêutica |
| ZA959469B (en) * | 1994-11-15 | 1996-05-15 | South African Druggists Ltd | Pharmaceutical composition |
| IT1283029B1 (it) * | 1996-05-17 | 1998-04-03 | Resa Farma | Composizioni farmaceutiche a base di diclofenac |
| DE19538555A1 (de) | 1995-10-17 | 1997-04-24 | Beiersdorf Ag | Gegen Akne und entzündete Comedonen wirksame Wirkstoffkombinationen |
| DE69727922T2 (de) * | 1996-04-16 | 2005-01-20 | Novartis Consumer Health S.A. | Schnell zerfallende orale dosierungsform |
| US20060013896A1 (en) | 1996-05-17 | 2006-01-19 | Giorgio Reiner | Methods of treating acute pain using diclofenac |
| US6974595B1 (en) | 1996-05-17 | 2005-12-13 | Proethic Pharmaceuticals, Inc. | Pharmaceutical compositions based on Diclofenae |
| US7687542B2 (en) * | 1996-05-17 | 2010-03-30 | Kowa Pharmaeuticals America, Inc. | Rapidly bioavailable tablet and capsule formulations of diclofenac |
| US5854279A (en) * | 1996-06-04 | 1998-12-29 | Eisai Co., Ltd | Therapeutic agent for dermatosis |
| US5914129A (en) | 1996-07-23 | 1999-06-22 | Mauskop; Alexander | Analgesic composition for treatment of migraine headaches |
| US6586458B1 (en) | 1996-08-16 | 2003-07-01 | Pozen Inc. | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
| US5788987A (en) | 1997-01-29 | 1998-08-04 | Poli Industria Chimica Spa | Methods for treating early morning pathologies |
| US6365180B1 (en) * | 1998-01-20 | 2002-04-02 | Glenn A. Meyer | Oral liquid compositions |
| TR200100708T2 (tr) | 1998-09-10 | 2001-07-23 | Nycomed Danmark A/S | İlaç maddelerine mahsus çabuk salımlı farmasötik bileşimler. |
| DK1312355T3 (da) * | 2001-11-20 | 2003-10-06 | Applied Pharma Res | Vandopløselige, ikke-brusende farmaceutiske præparater omfattende ikke-steroide antiinflammatoriske medikamenter |
| RU2202359C1 (ru) * | 2002-05-18 | 2003-04-20 | Агафонов Сергей Александрович | Лечебно-профилактическое средство |
| WO2004098561A2 (en) * | 2003-05-08 | 2004-11-18 | Nektar Therapeutics Uk Ltd | Particulate materials |
| JO3352B1 (ar) * | 2005-06-17 | 2019-03-13 | Apr Applied Pharma Res Sa | صيغ دايكلوفيناك وطرق استخدامه |
| US7939561B2 (en) * | 2006-02-07 | 2011-05-10 | Apr Applied Pharma Research S.A. | Blister packaging for acute pain regimens |
| US7700125B2 (en) * | 2006-02-07 | 2010-04-20 | Kowa Pharmaceuticals America, Inc. | Moisture resistant container systems for rapidly bioavailable dosage forms |
-
2006
- 2006-06-11 JO JOP/2006/0177A patent/JO3352B1/ar active
- 2006-06-12 TW TW095120788A patent/TW200740470A/zh unknown
- 2006-06-16 GT GT200600261A patent/GT200600261A/es unknown
- 2006-06-16 BR BRPI0612245-0A patent/BRPI0612245A2/pt not_active Application Discontinuation
- 2006-06-16 PL PL06743167T patent/PL1890680T3/pl unknown
- 2006-06-16 PT PT67431676T patent/PT1890680T/pt unknown
- 2006-06-16 CN CN201510144782.0A patent/CN104856959A/zh active Pending
- 2006-06-16 CA CA2932603A patent/CA2932603C/en active Active
- 2006-06-16 US US11/455,120 patent/US7759394B2/en active Active
- 2006-06-16 ES ES06743167.6T patent/ES2641889T3/es active Active
- 2006-06-16 EP EP11001797.7A patent/EP2402003B1/en active Active
- 2006-06-16 AU AU2006257072A patent/AU2006257072B2/en active Active
- 2006-06-16 NZ NZ564002A patent/NZ564002A/en unknown
- 2006-06-16 CN CNA2006800296269A patent/CN101272768A/zh active Pending
- 2006-06-16 ES ES13181615T patent/ES2717879T3/es active Active
- 2006-06-16 ES ES16157175T patent/ES2912897T3/es active Active
- 2006-06-16 CN CN202011532717.2A patent/CN112755014A/zh active Pending
- 2006-06-16 MX MX2007016072A patent/MX2007016072A/es active IP Right Grant
- 2006-06-16 PE PE2006000678A patent/PE20070074A1/es not_active Application Discontinuation
- 2006-06-16 CA CA2632375A patent/CA2632375C/en active Active
- 2006-06-16 KR KR1020087001172A patent/KR101352130B1/ko not_active Expired - Fee Related
- 2006-06-16 RU RU2008101784/15A patent/RU2432160C2/ru active
- 2006-06-16 WO PCT/EP2006/005799 patent/WO2006133954A2/en not_active Ceased
- 2006-06-16 TR TR2017/06038T patent/TR201706038T4/tr unknown
- 2006-06-16 EP EP06743167.6A patent/EP1890680B1/en active Active
- 2006-06-16 EP EP16157175.7A patent/EP3103441B1/en active Active
- 2006-06-16 EP EP13181615.9A patent/EP2705837B1/en active Active
- 2006-06-20 AR ARP060102600A patent/AR057378A1/es unknown
-
2007
- 2007-12-07 EC EC2007007989A patent/ECSP077989A/es unknown
- 2007-12-13 ZA ZA200710858A patent/ZA200710858B/xx unknown
-
2008
- 2008-01-17 NO NO20080352A patent/NO342336B1/no unknown
-
2009
- 2009-03-06 US US12/399,175 patent/US20090197961A1/en not_active Abandoned
-
2010
- 2010-01-07 US US12/683,517 patent/US8097651B2/en active Active
-
2013
- 2013-01-16 US US13/742,871 patent/US8927604B2/en active Active
-
2014
- 2014-11-06 US US14/534,428 patent/US9827197B2/en active Active
-
2016
- 2016-02-22 HK HK16101926.9A patent/HK1213814A1/zh unknown
-
2017
- 2017-05-24 US US15/604,479 patent/US20170319484A1/en not_active Abandoned
-
2019
- 2019-12-17 US US16/716,511 patent/US20200323776A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR057378A1 (es) | Formulaciones de diclofenac y metodos para usarlas | |
| ES2234025T5 (es) | Formulacion de agonistas de 5-ht. | |
| ES2564936T3 (es) | Aerosol nasal líquido que contiene naltrexona a dosis baja | |
| ES2553742T3 (es) | Forma de dosificación farmacéutica que comprende 6'-fluor-(N-metil- o N,N-dimetil)-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano[3,4,b]indol]-4-amina | |
| EP3478283A1 (en) | Use of neurokinin-1 antagonists to treat a variety of pruritic conditions | |
| AR037255A1 (es) | Composiciones farmaceuticas que contienen oxibutinina | |
| PT866713E (pt) | Meios de administração para fármacos analgésicos, anti-inflamatórios e antipiréticos contendo óxido de azoto e composições farmacêuticas contendo esses meios e fármacos | |
| AR035642A1 (es) | Uso de una composicion de celecoxib para el alivio rapido del dolor | |
| AR075735A1 (es) | Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso | |
| RU2010151952A (ru) | Водорастворимые аналоги ацетаминофена | |
| EP1058559B1 (en) | Combination of a selective nmda nr2b antagonist and a cox-2 inhibitor | |
| AR082803A1 (es) | Metodos y formulaciones para el tratamiento de la trombosis con betrixaban y un inhibidor de la glicoproteina p | |
| Huynh et al. | Current concepts in acute pain management | |
| US20050020657A1 (en) | Compositions and methods involving the combination of a thromboxane A2 receptor antagonist and an inhibitor of cyclooxygenase-2 | |
| PL190733B1 (pl) | Zastosowanie przeciwmigrenowej kombinacji i kompozycja farmaceutyczna do leczenia migreny | |
| BRPI0610663A2 (pt) | uso terapêutico de nefopam e seus análogos | |
| JP2017533956A (ja) | 筋肉痛を含む病態の治療のための組合せ | |
| US20150290174A1 (en) | Pharmaceutical formulations and method of using the same for alleviating symptoms of hangover, stomach flu or migraine | |
| CN101797243B (zh) | 一种含有左旋多巴和冰片的组合物及其应用 | |
| WO2019143234A1 (es) | Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco trometamina y clorhidrato de tramadol | |
| AU2005270573A1 (en) | Novel formulation for L-tryptophane comprising carbidopa/benserazide | |
| WO2007148950A1 (es) | Composición farmacéutica sinergística de ketorolaco y clonixinato de lisina | |
| Pepper | NONSTEROIDAL ANTIINFLAMMATORY DRUGS: New Perspectives on a Familiar Drug Class | |
| ZA200207701B (en) | Drug combination for the treatment of headache comprising mirtazapine and paracetamol or a non-steroidal anti-inflammatory drug. | |
| WO2015166418A2 (es) | Composición farmacéutica para el tratamiento de alopatías relacionadas con el dolor, usando como agente activo al ketorolaco trometamina y clorhidrato de tramadol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |